1. Immunotherapy

    Comments Leave a Comment

    1-15 of 204 1 2 3 4 ... 12 13 14 »
    1. Mentioned In 204 Articles

    2. Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO.

      ...nta A, Valteau-Couanet D, Janzek E, Hosten N, Zinke A, Barthlen W, Varol E, Loibner H, Ladenstein R, Lode HN Immunotherapy with short term infusion (STI) of monoclonal anti-GD2 antibody (mAb) ch14.18 (4 × 25mg/m2/d; 8-2...
      Read Full Article
    3. Neuroblastoma Patients' KIR and KIR-ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.

      ...mentary KIR/KIR-ligand genotypes, clinical outcome was not significantly different for patients that received immunotherapy vs. those receiving isotretinoin alone. These data show that administration of immunotherapy is ...
      Read Full Article
      Mentions: COG Immunotherapy
    4. Cell surface protein may offer big target in treating high-risk childhood cancers

      Cell surface protein may offer big target in treating high-risk childhood cancers
      ...neuroblastoma cells with no discernible toxicity to normal cells. "These findings establish that this type of immunotherapy could be potentially safe and effective against neuroblastoma," said Maris. "Our next steps will...
      Read Full Article
    5. Seattle Children's Opens CD22 CAR T-Cell Immunotherapy Trial for Children and Young Adults Whose Leukemia Escapes CD19 CAR T-Cell Therapy

      Seattle Children's Opens CD22 CAR T-Cell Immunotherapy Trial for Children and Young Adults Whose Leukemia Escapes CD19 CAR T-Cell Therapy
      ...mmunotherapy and cancer research, please visit Strong Against Cancer’s donation page. For more information on immunotherapy research trials at Seattle Children’s, please call (206) 987-2106 or email immunotherapy@seattle...
      Read Full Article
    6. Transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: A case series

      ... as a result of dinutuximab therapy has not been reported in clinical trials or in the published literature. Immunotherapy with the anti-GD2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeut...
      Read Full Article
    7. Seattle Children's opens CD22 CAR T-cell immunotherapy trial for children and young adults

      Seattle Children's opens CD22 CAR T-cell immunotherapy trial for children and young adults
      ...mmunotherapy and cancer research, please visit Strong Against Cancer's donation page. For more information on immunotherapy research trials at Seattle Children's, please call (206) 987-2106 or email immunotherapy@seattle...
      Read Full Article
    8. 1-15 of 204 1 2 3 4 ... 12 13 14 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Quotes about Immunotherapy

    1. Our data show that a certain combination of KIR-related genes may be predictive of benefit from immunotherapy.
      In Study Identifies Patients Who Benefit Most From Dinutuximab-based Immunotherapy
    2. It has been shown that immunotherapy works for some adult cancers; the question is, what impact will it have on childhood cancers?
      In Combining immunotherapies effective against mouse model of cancer
    3. We believe T-cell immunotherapy has tremendous potential.
      In Seattle Children's Opens CD22 CAR T-Cell Immunotherapy Trial for Children and Young Adults Whose Leukemia Escapes CD19 CAR T-Cell Therapy